Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes-Reference-Cited by-同舟云学术

Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes

Published:2015-10-29 Issue:11 Volume:4 Page:669-679
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Rotroff DM¹²,Shahin MH³,Gurley SB⁴,Zhu H⁵,Motsinger‐Reif A¹²,Meisner M²,Beitelshees AL⁶,Fiehn O⁷⁸,Johnson JA³,Elbadawi‐Sidhu M⁷,Frye RF³,Gong Y³,Weng L³,Cooper‐DeHoff RM³,Kaddurah‐Daouk R⁵⁹

Affiliation:

1. Department of StatisticsNorth Carolina State UniversityRaleigh North Carolina USA

2. Bioinformatics Research CenterNorth Carolina State UniversityRaleigh North Carolina USA

3. Department of Pharmacotherapy and Translational Research and Center for PharmacogenomicsUniversity of FloridaGainesville Florida USA

4. Department of MedicineDuke University Medical Center and Durham Veterans Affairs Medical CenterDurham North Carolina USA

5. Department of Psychiatry and Behavioral SciencesDuke UniversityDurham North Carolina USA

6. Department of MedicineUniversity of Maryland School of MedicineBaltimore Maryland USA

7. UC Davis Genome CenterUniversity of California DavisDavis California USA

8. King Abdulaziz UniversityJeddah Saudi‐Arabia

9. Duke Institute for Brain SciencesDuke UniversityDurham North California USA

Publisher

Wiley

Subject

Pharmacology (medical),Modelling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12017

Reference43 articles.

1. Executive Summary: Heart Disease and Stroke Statistics—2015 Update

2. Global burden of hypertension: analysis of worldwide data

3. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults

4. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

5. Clinical Events in High-Risk Hypertensive Patients Randomly Assigned to Calcium Channel Blocker Versus Angiotensin-Converting Enzyme Inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics in Pharmacometabolomics: Towards Personalized Medication;Pharmaceuticals;2023-11-07

2. Pharmacometabolomics: General Applications of Metabolomics in Drug Development and Personalized Medicine;Metabolomics;2023

3. Influence of Genetic West African Ancestry on Metabolomics among Hypertensive Patients;Metabolites;2022-08-24

4. Application of omics in hypertension and resistant hypertension;Hypertension Research;2022-03-09

5. Personalizing treatments for patients based on cardiovascular phenotyping;Expert Review of Precision Medicine and Drug Development;2022-01-02